A Randomized Multicenter Phase 2 Study of PLX3397 Plus Decitabine Versus Decitabine Alone in Subjects with Newly Diagnosed FLT3-ITD-positive Acute Myeloid Leukemia Who Are 60 Years of Age or Older and Who Are Not Candidates for Intensive Chemotherapy

Trial Profile

A Randomized Multicenter Phase 2 Study of PLX3397 Plus Decitabine Versus Decitabine Alone in Subjects with Newly Diagnosed FLT3-ITD-positive Acute Myeloid Leukemia Who Are 60 Years of Age or Older and Who Are Not Candidates for Intensive Chemotherapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2015

At a glance

  • Drugs Pexidartinib (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top